company-header-background

GenVoy-ILM™

Non-Viral LNP Delivery for RNA

Overview
GenVoy-ILM™ is an ionizable lipid mix that enables the rapid and easy production of RNA-loaded lipid nanoparticles (LNPs) using the NanoAssemblr®Platform.  GenVoy-ILM is the simplest way to get started with LNPs - the most advanced non-viral technology for delivering nucleic acids.

An exclusive ionizable cationic lipid mix for preclinical development:

  • • Gene Therapy
  • • Cell Therapy
  • • Vaccine

 

With applications in oncology, rare diseases, and infectious diseases.

LNPs mimic low-density lipoproteins and are taken up through an endogenous pathway where they are designed to trigger the release of nucleic acids in the cytoplasm.

Endogenous Uptake

 

 

Screen Shot 2019-06-21 at 2.58.04 PM

Deliver siRNA for sustained gene knockdown


A single injection of GenVoy-ILM Luciferase mRNA-LNP was administered to mice via the tail vein at an RNA dose of 1 mg/mL. Luciferase expression was measured by 6-hours post-mRNA-LNP administration.

 

 

Deliver mRNA for gene expression


A single injection of GenVoy-ILM Factor VII siRNA-LNP was administered to mice via the tail vein at the RNA doses indicated and plasma levels of Factor VII protein were measured up to 21 days post-administration.
Asset 1

Lipid Nanoparticles

LNPs contain a pH-sensitive ionizable cationic lipid that attract anionic nucleic acids to form the core of self-assembling nanoparticle to ensure high encapsulation.

 

At physiological pH, LNPs are neutral, eliminating a mechanism of toxicity seen with permanently cationic molecules.

 

These same pH-sensitive lipids are responsible for responding to the acidic environment of the endosome and triggering the disruption of the endosome and release of the nucleic acid into the cell.

Nucleic Acid Lipid Nanoparticle

Both The Chemistry And The Process Determine The Outcome

 

LNPs made with the NanoAssemblr®Platform have a unique homogeneous structure that is more effective compared to other methods of manufacture such as T-tube mixing. 



NanoAssemblr v Conventional T-tube
LNPs made with NanoAssemblr® Technology and containing siRNA against Factor VII results in more effective in vivo gene knockdown than those made with a T-junction. Lower bars indicate more effective knockdown of Factor VII measured in serum of mice treated intravenously with the indicated dose of siRNA.

Product Information

GenVoy-ILM is a pre-blended lipid mix in ethanol and is available in two formats with or without added dye for visualization.

 

• 2 mL

• 5 mL

GenVoy-ILM Vials

The Chemistry And The Process Affect The Outcome 

LNPs made with the NanoAssemblr platform exhibit a unique homogeneous core structure with exceptionally consistent size within and between batches, which has been shown to be more potent than particles made by other methods. 

 

 

Screen Shot 2019-06-13 at 4.30.52 PM

 

 

Use Genvoy-ILM for: 

  • • Gene silencing 
  • • Gene expression 
  • • Gene editing 
  • • Gene modulation 

Use GenVoy-ILM to encapsulate and deliver RNA: 

  • • siRNA 
  • • miRNA 
  • • tRNA 
  • • gRNA 
  • • mRNA 

Get Started

To learn how Precision NanoSystems accelerates nanomedicine development from an idea to clinical applications, contact our Technical Sales Team.

Get in Touch

Resource Center

Poster

July 01, 2018

Robust low-volume production of nanoparticles for genetic manipulation of cells

Read More 阅读更多 PDF

Publication - Abstract

January 14, 2018

The Journal of Physical Chemistry

Structure of Lipid Nanoparticles Containing siRNA or mRNA by Dynamic Nuclear Polarization-Enhanced NMR Spectroscopy

J. Viger-Gravel, A. Schantz, A. Pinon, A. Rossini , S. Schantz, and L. Emsley

Read More 阅读更多

Video

July 26, 2016

Liposomes: from Prototype to the Clinic | Norbert Maurer, Transferra Nanosciences

Read More 阅读更多

Webinar

November 08, 2017

Nano-sized Delivery Systems for Vaccines—Precision NanoSystems Webinar 2017

Read More 阅读更多

Publication - Abstract

February 19, 2014

Drug Delivery and Translational Research

Lipid Nanoparticle Delivery Systems for siRNA-Based Therapeutics

Wan C, Allen TM, Cullis PR

Read More 阅读更多

Video

July 26, 2016

Targeted mRNA delivery to the Liver for I-ERT | Pierrot Harvie, PhaseRX

Read More 阅读更多
Resource Center 资源中心

Stay Informed

Sign up today to automatically receive new Precision NanoSystems application notes, conference posters, relevant science publications, and webinar invites.

MENU
菜单
X
X